RxDoctor Payments Data

Melena Bellin, MD

Pediatric Endocrinology · Minneapolis, MNNPI 1124219043

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $47,474 of the $56,256 with a category attached, or 84.4%. Vertex accounts for 85.3% of it on its own, with 5 other manufacturers making up the rest.

$56,256in general payments, 2019–2025

Across 80 payments — averaging $703.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$48K
  • Novo Nordisk AS$8K
  • Medtronic$175
  • Insulet Corporation$162
  • Boston Scientific$77
  • Sanofi-aventis U.S. LLC$73
$94,599in research payments, 2019–2025

Across 8 payments — averaging $11,825 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vertex$90K
  • Dexcom, Inc.$3K
  • Insulet Corporation$2K

What the payments were for

  • Consulting fees$47,47484%
  • Travel & lodging$7,53713%
  • Food & beverage$1,2452%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Vertex67$47,966
Novo Nordisk AS6$7,802
Medtronic(2 entities)3$175
Insulet Corporation2$162
Boston Scientific1$77
Sanofi-aventis U.S. LLC1$73

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,256 in reported general payments places this provider in the 80th percentile of 25 pediatric endocrinology providers in Minnesota.

See all pediatric endocrinology providers in Minnesota

Medicare billing

Part B allowed, 2024
$3,333
Medicare patients
15
Services billed
33

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase38$124,132
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/719$22,793
Mycophenolic AcidMycophenolate Sodium25$7,700
Tacrolimus83$5,200
Nano 2nd Gen Pen NeedlePen Needle, Diabetic13$1,499
Mycophenolate Mofetil14$1,468
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,238
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim17$100

Paid to pharmacies, not to this prescriber.

Other pediatric endocrinology in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →